Stanford to limit drug maker financing
Stanford University is expected to announce that it will severely restrict industry financing of doctors' continuing education at its medical school. The move is due to concern about the influence drug companies may have on medical education. Nearly all doctors in the country must take annual refresher courses that drug makers have long paid for, but Stanford will no longer let drug and device companies specify which courses they wish to finance. Instead, companies will be asked to contribute only to a schoolwide pool of money that can be used for any class, even ones that never mention a company's products.
- ICD-10 Delay Alters Provider, Vendor Prep
- Providers Lag as Consumers Set Agenda
- Payment Reform Naysayers 'Better Wake Up'
- As Hospitalist Patient Loads Rise, So Do Hospital Costs
- Crisis Spurs Healthcare Payment Reform in Arkansas
- HIT Leaders Want Flexibility, Transparency from Next HHS Chief
- Esther Dyson Launches Population Health Challenge
- Reduce Readmissions by Activating Patients to Do 'Self-Care'
- Advance Directives: Let's Make a Law
- Hire Care Coordinators Strategically